5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

BACKGROUND: Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. METHODS: In this multicenter, prospective, observational study of adults treated with MEC whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsui, Reiko, Suzuki, Kenichi, Takiguchi, Tomomi, Nishio, Makoto, Koike, Takeshi, Hayashi, Toshinobu, Seto, Takashi, Kogure, Yuki, Nogami, Naoyuki, Fujiwara, Kimiko, Kaneda, Hiroyasu, Harada, Tomohiko, Shimizu, Satoru, Kimura, Masashi, Kenmotsu, Hirotsugu, Shimokawa, Mototsugu, Goto, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539512/
https://www.ncbi.nlm.nih.gov/pubmed/33023657
http://dx.doi.org/10.1186/s40360-020-00445-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539512/
https://www.ncbi.nlm.nih.gov/pubmed/33023657
http://dx.doi.org/10.1186/s40360-020-00445-y

Ejemplares similares